A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting
Sign Up to like & getrecommendations! Published in 2017 at "Neurological Sciences"
DOI: 10.1007/s10072-017-3053-z
Abstract: Abnormal levels of beta amyloid (Aβ42) and tau protein concentrations in the cerebral spinal fluid (CSF) have been largely described in Alzheimer’s disease (AD). Thus, CSF analysis of these biomarkers has been incorporated in recent… read more here.
Keywords: clinical setting; dementia; csf; ftd clinical ... See more keywords